---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-290176"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2022-11-22T23:59:59+00:00"
generated_at: "2026-06-21T14:04:44.055080+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CytomX and Regeneron enter $30M upfront cancer bi-specific collaboration; up to $2B milestones

## Summary
- CytomX receives $30M upfront from Regeneron; eligible for up to $2B in development/regulatory milestones.
- Tiered royalties from high single digit to low-teen percentages on global net sales of licensed products.
- Collaboration uses CytomX's Probody platform and Regeneron's Veloci-Bi bispecific platform for conditionally-activated cancer therapies.
- Regeneron fully funds all preclinical, development, manufacturing, and commercialization activities worldwide.
- CytomX grants exclusive worldwide royalty-bearing license to Regeneron for oncology; Regeneron may terminate programs on 30 days' notice after 2 years.

## SEC filing metadata
- accession: 0001193125-22-290176
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2022-11-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312522290176/0001193125-22-290176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312522290176/d402086d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-290176
- JSON: https://secwatch.observer/filing/0001193125-22-290176.json
- Plain text: https://secwatch.observer/filing/0001193125-22-290176.txt

## Key facts
- Material Agreements
  CytomX Therapeutics, Inc. entered into Collaboration and License Agreement with Regeneron Pharmaceuticals Inc. valued at $30 million (effective 2022-11-16).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Regeneron Pharmaceuticals Inc.
  - Value: $30 million
  - Effective: 2022-11-16
  source text: On November 16, 2022, CytomX Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with Regeneron Pharmaceuticals Inc. (“Regeneron”), pursuant to which the Company and Regeneron will collaborate on the creation of conditionally-activated investigational bispecific cancer therapies utilizing the Company’s Probody ® therapeutic platform and Regeneron’s Veloci-Bi ® bispecific antibody development platform.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312522290176/0001193125-22-290176-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.